{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:48:15Z","timestamp":1791568095695,"version":"4.3.4"},"reference-count":181,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.autrev.2020.102738","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T02:49:52Z","timestamp":1608000592000},"page":"102738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019 Consensus"],"prefix":"10.1016","volume":"20","author":[{"given":"Roberto","family":"Giacomelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Afeltra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Coloma-Baz\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Foulquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Daniela","family":"Grembiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Kahaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Naty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Pers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Priori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Rivellese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Ruffatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Triolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102738_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0010","doi-asserted-by":"crossref","first-page":"102469","DOI":"10.1016\/j.autrev.2020.102469","article-title":"Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review","volume":"19","author":"Lee","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.imlet.2017.08.002","article-title":"Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges","volume":"190","author":"Tavakolpour","year":"2017","journal-title":"Immunol Lett."},{"key":"10.1016\/j.autrev.2020.102738_bb0020","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0030","first-page":"560","article-title":"Personalized medicine: part 1: evolution and development into theranostics","volume":"35","author":"Vogenberg","year":"2010","journal-title":"P T."},{"key":"10.1016\/j.autrev.2020.102738_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.autrev.2011.07.006","article-title":"Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events","volume":"11","author":"Murdaca","year":"2011","journal-title":"Autoimmun Rev."},{"issue":"2","key":"10.1016\/j.autrev.2020.102738_bb0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.autrev.2009.03.010","article-title":"Prospective new biological therapies for rheumatoid arthritis","volume":"9","author":"Senolt","year":"2009","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0045","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev."},{"issue":"6","key":"10.1016\/j.autrev.2020.102738_bb0055","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"20","key":"10.1016\/j.autrev.2020.102738_bb0060","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","article-title":"Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells","volume":"84","author":"Gauldie","year":"1987","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.autrev.2020.102738_bb0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","article-title":"Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice","volume":"53","author":"Pers","year":"2014","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.autrev.2020.102738_bb0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.autrev.2020.102738_bb0075","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3109\/s10165-012-0825-4","article-title":"Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab","volume":"23","author":"Hoshi","year":"2013","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/acr.22765","article-title":"Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis","volume":"68","author":"Wang","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.autrev.2020.102738_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","article-title":"Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study","volume":"18","author":"Bay-Jensen","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.autrev.2020.102738_bb0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/14397595.2019.1621026","article-title":"Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study","volume":"30","author":"Kato","year":"2020","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.semarthrit.2015.07.001","article-title":"Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice","volume":"45","author":"Narv\u00e1ez","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0100","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","article-title":"Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register","volume":"54","author":"Forsblad-d\u2019Elia","year":"2015","journal-title":"Rheumatology (Oxford)."},{"issue":"12","key":"10.1016\/j.autrev.2020.102738_bb0105","doi-asserted-by":"crossref","first-page":"e0145468","DOI":"10.1371\/journal.pone.0145468","article-title":"Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Na\u00efve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)","volume":"10","author":"Izumi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102738_bb0110","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0895-4356(96)00025-X","article-title":"Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis","volume":"49","author":"Sun","year":"1996","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.autrev.2020.102738_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.2044-8317.1992.tb00992.x","article-title":"Backward, forward and stepwise automated subset selection algorithms: Frequency of obtaining authentic and noise variables","volume":"45","author":"Shelley Derksen","year":"1992","journal-title":"Br J Math Stat Psychol."},{"key":"10.1016\/j.autrev.2020.102738_bb0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.2517-6161.1983.tb01258.x","article-title":"Regression, prediction and shrinkage (with discussion)","volume":"45","author":"Copas","year":"1983","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"10.1016\/j.autrev.2020.102738_bb0125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0130","series-title":"World Health Organ Tech Rep Ser","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","year":"2000"},{"key":"10.1016\/j.autrev.2020.102738_bb0135","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/rheumatology\/keq266","article-title":"Obesity in rheumatoid arthritis","volume":"50","author":"Stavropoulos-Kalinoglou","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.autrev.2020.102738_bb0140","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.autrev.2020.102738_bb0145","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3899\/jrheum.150224","article-title":"Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis: A Systematic Review and Metaanalysis","volume":"42","author":"Vidal","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/acr.22932","article-title":"Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"69","author":"Liu","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.autrev.2020.102738_bb0155","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2016.10.011","article-title":"The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study","volume":"84","author":"Mariette","year":"2017","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.autrev.2020.102738_bb0160","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","article-title":"Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis","volume":"36","author":"D\u2019Agostino","year":"2017","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0165","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10067-016-3505-5","article-title":"Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the pan-European registry collaboration for abatacept (PANABA)","volume":"36","author":"Iannone","year":"2017","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cmi.2015.07.004","article-title":"Strengths and limitations of industry vs. academic randomized controlled trials","volume":"21","author":"Laterre","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.autrev.2020.102738_bb0175","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/eci.12691","article-title":"Body mass index and response to abatacept in rheumatoid arthritis","volume":"46","author":"Gardette","year":"2016","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.autrev.2020.102738_bb0180","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10067-016-3220-2","article-title":"No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study","volume":"35","author":"Kim","year":"2016","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","article-title":"Obesity reduces the drug survival of second line biological drugs following a first TNF-\u03b1 inhibitor in rheumatoid arthritis patients","volume":"82","author":"Iannone","year":"2015","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.autrev.2020.102738_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2019.05.017","article-title":"Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study","volume":"66","author":"Di Carlo","year":"2019","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0195","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3899\/jrheum.140673","article-title":"Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient","volume":"42","author":"Pers","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0200","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2020.102738_bb0210","first-page":"478","article-title":"Body mass index and response to infliximab in rheumatoid arthritis","volume":"33","author":"Ottaviani","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0215","doi-asserted-by":"crossref","first-page":"e000458","DOI":"10.1136\/rmdopen-2017-000458","article-title":"Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial","volume":"3","author":"Levitsky","year":"2017","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.autrev.2020.102738_bb0220","article-title":"Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial","volume":"20","author":"Smolen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102738_bb0225","first-page":"422","article-title":"Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis","volume":"37","author":"McCulley","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0230","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jbspin.2015.02.011","article-title":"Body Mass Index and response to rituximab in rheumatoid arthritis","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.autrev.2020.102738_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181203","article-title":"Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study","volume":"12","author":"Ruscitti","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.autrev.2020.102738_bb0240","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.autrev.2020.102738_bb0245","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1586\/1744666X.2016.1168293","article-title":"IL-1\u03b2 at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?","volume":"12","author":"Giacomelli","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.autrev.2020.102738_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002901","article-title":"Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial","volume":"16","author":"Ruscitti","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0255","doi-asserted-by":"crossref","first-page":"e14587","DOI":"10.1097\/MD.0000000000014587","article-title":"IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study","volume":"98","author":"Ruscitti","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2020.102738_bb0260","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0265","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0270","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0275","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0280","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/ard.2009.119222","article-title":"Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate","volume":"69","author":"Cohen","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0285","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3899\/jrheum.090442","article-title":"Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0290","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102738_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0300","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.autrev.2020.102738_bb0305","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0310","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar3901","article-title":"B lymphocyte-typing for prediction of clinical response to rituximab","volume":"14","author":"Brezinschek","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.autrev.2020.102738_bb0315","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3899\/jrheum.111488","article-title":"Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion","volume":"40","author":"V\u00e1ncsa","year":"2013","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0320","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0325","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/art.30599","article-title":"Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0330","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","article-title":"Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment","volume":"62","author":"Vital","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0335","doi-asserted-by":"crossref","first-page":"101ra92","DOI":"10.1126\/scitranslmed.3002432","article-title":"A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis","volume":"3","author":"Owczarczyk","year":"2011","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0340","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/kes344","article-title":"Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients","volume":"52","author":"Ruyssen-Witrand","year":"2013","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.autrev.2020.102738_bb0345","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/annrheumdis-2012-202435","article-title":"The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study","volume":"73","author":"Quartuccio","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0350","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.autrev.2010.06.012","article-title":"The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis","volume":"11","author":"Fabris","year":"2012","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0355","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","article-title":"Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial","volume":"66","author":"Sellam","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0360","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13075-016-1190-z","article-title":"Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis","volume":"18","author":"Sellam","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.autrev.2020.102738_bb0365","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/art.38023","article-title":"CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis","volume":"65","author":"Sellam","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0370","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","article-title":"Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment","volume":"56","author":"Teng","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0375","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0380","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0385","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab\u2019s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0390","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0395","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/ard.2009.126441","article-title":"Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity","volume":"69","author":"Kormelink","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0400","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/keq337","article-title":"CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis","volume":"50","author":"Rosengren","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.autrev.2020.102738_bb0405","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","article-title":"Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab","volume":"71","author":"Hogan","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0410","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.autrev.2020.102738_bb0415","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102738_bb0420","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/1744666X.2019.1627876","article-title":"An update on pathogenesis of psoriatic arthritis and potential therapeutic targets","volume":"15","author":"Chimenti","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.autrev.2020.102738_bb0425","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","volume":"48-49","author":"Raychaudhuri","year":"2014","journal-title":"J Autoimmun."},{"key":"10.1016\/j.autrev.2020.102738_bb0430","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/2040622315608647","article-title":"Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies","volume":"6","author":"Caso","year":"2015","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0435","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0440","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11926-019-0856-3","article-title":"The pathogenesis of ankylosing spondylitis: an update","volume":"21","author":"Pedersen","year":"2019","journal-title":"Curr Rheumatol Rep."},{"key":"10.1016\/j.autrev.2020.102738_bb0445","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.33415","article-title":"HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open."},{"key":"10.1016\/j.autrev.2020.102738_bb0455","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/rheumatology\/kew230","article-title":"Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics","volume":"55","author":"Sieper","year":"2016","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.autrev.2020.102738_bb0460","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.160958","article-title":"Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry","volume":"44","author":"Glintborg","year":"2017","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0465","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0470","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.141278","article-title":"Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials","volume":"42","author":"Baraliakos","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0475","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0480","doi-asserted-by":"crossref","first-page":"513782","DOI":"10.1155\/2013\/513782","article-title":"Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues","volume":"2013","author":"Caso","year":"2013","journal-title":"Int J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0485","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s10067-018-4209-9","article-title":"From autoinflammation to autoimmunity: old and recent findings","volume":"37","author":"Caso","year":"2018","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194693","article-title":"Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNF\u03b1 therapy","volume":"13","author":"Aita","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.autrev.2020.102738_bb0495","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.semarthrit.2019.04.007","article-title":"Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases","volume":"48","author":"Tanaka","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0500","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102738_bb0505","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"33","author":"Xueyi","year":"2013","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.autrev.2020.102738_bb0510","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/art.21914","article-title":"Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis","volume":"54","author":"Kruithof","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0515","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar3228","article-title":"Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study","volume":"13","author":"Pontifex","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.autrev.2020.102738_bb0520","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ard.2008.091389","article-title":"A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue","volume":"68","author":"van Kuijk","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0525","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/prca.201500051","article-title":"A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-\u03b1 treatment of psoriatic arthritis","volume":"10","author":"Collins","year":"2016","journal-title":"Proteomics Clin Appl."},{"key":"10.1016\/j.autrev.2020.102738_bb0530","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0535","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2019.03.004","article-title":"Refractory lupus nephritis: When, why and how to treat","volume":"18","author":"Kronbichler","year":"2019","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0540","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0545","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.autrev.2020.102738_bb0550","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: A meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0555","first-page":"6","article-title":"Tacrolimus is effective for lupus nephritis patients with persistent proteinuria","volume":"28","author":"Uchino","year":"2010","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0560","first-page":"62","article-title":"Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study","volume":"31","author":"Fei","year":"2013","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0565","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0961203318758505","article-title":"Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis","volume":"27","author":"Choi","year":"2018","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2020.102738_bb0570","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/rheumatology\/keu265","article-title":"Long-term data on tacrolimus treatment in lupus nephritis","volume":"53","author":"Yap","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.autrev.2020.102738_bb0575","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12013-014-0437-z","article-title":"Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys."},{"key":"10.1016\/j.autrev.2020.102738_bb0580","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfp002","article-title":"Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study","volume":"24","author":"Boletis","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.autrev.2020.102738_bb0585","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-015-3166-9","article-title":"Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review","volume":"35","author":"Contis","year":"2016","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0590","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0961203313483376","article-title":"Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis","volume":"22","author":"Davies","year":"2013","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2020.102738_bb0595","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/rheumatology\/kes348","article-title":"Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response","volume":"52","author":"J\u00f3nsd\u00f3ttir","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102738_bb0600","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14397595.2015.1060665","article-title":"Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0605","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0961203309351541","article-title":"Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients","volume":"19","author":"Garcia-Carrasco","year":"2010","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2020.102738_bb0610","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.autrev.2020.102738_bb0615","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.thromres.2004.08.006","article-title":"Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials","volume":"114","author":"Lassere","year":"2004","journal-title":"Thromb Res."},{"key":"10.1016\/j.autrev.2020.102738_bb0620","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11926-013-0403-6","article-title":"Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?","volume":"16","author":"de Jes\u00fas","year":"2014","journal-title":"Curr Rheumatol Rep."},{"key":"10.1016\/j.autrev.2020.102738_bb0625","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/14397595.2014.942503","article-title":"Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications","volume":"25","author":"Matsuki","year":"2015","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0630","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102738_bb0635","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol."},{"key":"10.1016\/j.autrev.2020.102738_bb0640","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0645","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1600-0412.2011.01236.x","article-title":"High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome","volume":"90","author":"Simchen","year":"2011","journal-title":"Acta Obstet Gynecol Scand."},{"key":"10.1016\/j.autrev.2020.102738_bb0650","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/0961203309347794","article-title":"Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome","volume":"19","author":"Bramham","year":"2010","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2020.102738_bb0655","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.autrev.2018.03.018","article-title":"Antiphospholipid syndrome: An update on risk factors for pregnancy outcome","volume":"17","author":"De Carolis","year":"2018","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0660","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0665","first-page":"639","article-title":"Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study","volume":"118","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.autrev.2020.102738_bb0670","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJM199707173370302","article-title":"Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss","volume":"337","author":"Laskin","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0675","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.autrev.2020.102738_bb0680","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.transci.2019.07.009","article-title":"Therapeutic apheresis during pregnancy: A single center experience","volume":"58","author":"Colpo","year":"2019","journal-title":"Transfus Apher Sci."},{"key":"10.1016\/j.autrev.2020.102738_bb0685","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12016-016-8569-0","article-title":"Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy","volume":"53","author":"Mayer-Pickel","year":"2017","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.autrev.2020.102738_bb0690","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1160\/TH14-03-0191","article-title":"Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study","volume":"112","author":"Ruffatti","year":"2014","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.autrev.2020.102738_bb0695","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.transci.2015.11.006","article-title":"Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block","volume":"53","author":"Ruffatti","year":"2015","journal-title":"Transfus Apher Sci."},{"key":"10.1016\/j.autrev.2020.102738_bb0700","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jri.2016.03.004","article-title":"Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study","volume":"115","author":"Ruffatti","year":"2016","journal-title":"J Reprod Immunol."},{"issue":"8","key":"10.1016\/j.autrev.2020.102738_bb0705","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"Lefkou","year":"2016","journal-title":"J Clin Invest."},{"key":"10.1016\/j.autrev.2020.102738_bb0710","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2019.02.006","article-title":"Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases","volume":"49","author":"Alijotas-Reig","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0715","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jth.12264","article-title":"Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile","volume":"11","author":"Pengo","year":"2013","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.autrev.2020.102738_bb0720","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0725","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1157\/13115821","article-title":"Retirada de la anticoagulaci\u00f3n en el s\u00edndrome antifosfol\u00edpido primario cuando se negativizan los anticuerpos anticardiolipina [Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative]","volume":"208","author":"Criado-Garc\u00eda","year":"2008","journal-title":"Rev Clin Esp."},{"issue":"2\u20133","key":"10.1016\/j.autrev.2020.102738_bb0730","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12026-013-8407-x","article-title":"Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative","volume":"56","author":"Coloma Baz\u00e1n","year":"2013","journal-title":"Immunol Res."},{"key":"10.1016\/j.autrev.2020.102738_bb0735","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0961203317699285","article-title":"Cessation of oral anticoagulants in antiphospholipid syndrome","volume":"26","author":"Comarmond","year":"2017","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2020.102738_bb0740","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.semarthrit.2017.05.001","article-title":"Serological evolution in women with positive antiphospholipid antibodies","volume":"47","author":"Riancho-Zarrabeitia","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0745","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/RHU.0000000000000538","article-title":"Could Anticoagulation or Antiaggregation Treatment Be Ceased in Patients With Primary Antiphospholipid Syndrome When Antiphospholipid Antibodies Become Persistently Negative?","volume":"23","author":"Hindilerden","year":"2017","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0750","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0961203317721751","article-title":"Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study","volume":"27","author":"Yelnik","year":"2018","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2020.102738_bb0755","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren\u2019s syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102738_bb0760","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/1744666X.2014.891439","article-title":"B-cell hyperactivity in primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Kroese","year":"2014","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.autrev.2020.102738_bb0765","doi-asserted-by":"crossref","first-page":"102316","DOI":"10.1016\/j.jaut.2019.102316","article-title":"Predictive markers of lymphomagenesis in Sj\u00f6gren\u2019s syndrome: From clinical data to molecular stratification","volume":"104","author":"Kapsogeorgou","year":"2019","journal-title":"J Autoimmun."},{"issue":"Suppl. 118","key":"10.1016\/j.autrev.2020.102738_bb0770","first-page":"217","article-title":"B cell depletion with rituximab in the treatment of primary Sj\u00f6gren\u2019s syndrome: what have we learnt?","volume":"37","author":"Grigoriadou","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0775","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren\u2019s Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0780","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0785","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.autrev.2020.102738_bb0790","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0795","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0800","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0805","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0810","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome: an open-label clinical trial and mechanistic analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2020.102738_bb0815","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren\u2019s syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0820","first-page":"443","article-title":"Efficacy of retreatment with rituximab in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"33","author":"Meiners","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.autrev.2020.102738_bb0825","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0830","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaut.2015.11.002","article-title":"Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Cornec","year":"2016","journal-title":"J Autoimmun."},{"key":"10.1016\/j.autrev.2020.102738_bb0835","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards personalised treatment in primary Sj\u00f6gren\u2019s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0840","author":"Tarn","year":"2019","journal-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials."},{"key":"10.1016\/j.autrev.2020.102738_bb0845","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.autrev.2020.102738_bb0850","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.autrev.2020.102738_bb0855","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.autrev.2020.102738_bb0860","first-page":"IT7","article-title":"Rapid progress in our understanding of immune function promises more effective treatments for autoimmune disorders","volume":"18","author":"Autoimmune Disease","year":"2000","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.autrev.2020.102738_bb0865","doi-asserted-by":"crossref","first-page":"102508","DOI":"10.1016\/j.autrev.2020.102508","article-title":"Precision health: A pragmatic approach to understanding and addressing key factors in autoimmune diseases","volume":"19","author":"Conrad","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0870","doi-asserted-by":"crossref","first-page":"102506","DOI":"10.1016\/j.autrev.2020.102506","article-title":"Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease","volume":"19","author":"Mahler","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0875","doi-asserted-by":"crossref","first-page":"102515","DOI":"10.1016\/j.autrev.2020.102515","article-title":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","volume":"19","author":"Smeets","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0880","doi-asserted-by":"crossref","first-page":"102509","DOI":"10.1016\/j.autrev.2020.102509","article-title":"Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors","volume":"19","author":"Bodio","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0885","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: Predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0890","doi-asserted-by":"crossref","first-page":"102514","DOI":"10.1016\/j.autrev.2020.102514","article-title":"Usefulness of vasculitis biomarkers in the era of the personalized medicine","volume":"19","author":"Csernok","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0895","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2020.102738_bb0900","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000870","article-title":"Window of opportunity in rheumatoid arthritis definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD Open."},{"key":"10.1016\/j.autrev.2020.102738_bb0905","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.autrev.2017.01.014","article-title":"Effects of targeted therapies on the bone in arthritides","volume":"16","author":"Szentp\u00e9tery","year":"2017","journal-title":"Autoimmun Rev."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:21:58Z","timestamp":1761600118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220303190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":181,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1568997220303190"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102738","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019 Consensus","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102738"}}